Wall Street analysts expect Axovant Gene Therapies Ltd (NASDAQ:AXGT) to report earnings of ($0.63) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Axovant Gene Therapies earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.66). Axovant Gene Therapies posted earnings of ($2.16) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 70.8%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 6th.

According to Zacks, analysts expect that Axovant Gene Therapies will report full-year earnings of ($3.56) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($1.84). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.29) per share, with EPS estimates ranging from ($2.84) to ($1.20). Zacks Investment Researchs earnings per share calculations are an average based on a survey of sell-side research analysts that follow Axovant Gene Therapies.

A number of equities research analysts have recently issued reports on AXGT shares. ValuEngine upgraded shares of Axovant Gene Therapies from a sell rating to a hold rating in a research report on Thursday, August 1st. Robert W. Baird upgraded Axovant Gene Therapies from a neutral rating to an outperform rating and cut their price objective for the stock from $16.00 to $13.00 in a research report on Monday, August 12th. Zacks Investment Research upgraded Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 price objective for the company in a research report on Wednesday, November 13th. Finally, Chardan Capital lifted their price objective on Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a buy rating in a research report on Monday, October 28th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Axovant Gene Therapies presently has a consensus rating of Buy and an average target price of $24.72.

Several hedge funds and other institutional investors have recently made changes to their positions in AXGT. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies during the 2nd quarter valued at $1,482,000. Jane Street Group LLC lifted its holdings in shares of Axovant Gene Therapies by 28.8% during the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock valued at $289,000 after acquiring an additional 10,375 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Axovant Gene Therapies by 955.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock valued at $27,000 after acquiring an additional 3,821 shares in the last quarter. 13.84% of the stock is owned by institutional investors.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Are sell-side analysts objective?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Original post:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Expected to Post Earnings of -$0.63 Per Share - Mitchell Messenger

Comments are closed.